Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05030441 · ClinicalTrials.gov registry record · Phase 2
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
A Phase 2 study of Clonal Cytopenia of Undetermined Significance, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05030441 is a Phase 2 study of Clonal Cytopenia of Undetermined Significance that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 435-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05030441, a Phase 2 study of Clonal Cytopenia of Undetermined Significance, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients. The study will also be offered in a decentralized, remote structure to patients.
Conditions Studied
Interventions
- DRUG Ivosidenib
Study Locations (2)
Missouri
- Washington University School of Medicine - St Louis
Ohio
- Cleveland Clinic - Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05030441
The ClinicalTrials.gov registry entry for NCT05030441 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 435-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (95% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clonal Cytopenia of Undetermined Significance appearing as the primary indexed condition, and to 1 intervention - of which Ivosidenib is the first listed.
NCT05030441 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT05030441 about?
NCT05030441 is a clinical study titled "Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1". This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood ...
What is the current status of trial NCT05030441?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-04-01. Estimated completion is 2030-01-31.
What conditions does trial NCT05030441 study?
This clinical trial studies the following conditions: Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT05030441?
The interventions under investigation include: Ivosidenib (DRUG).
Who is sponsoring clinical trial NCT05030441?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05030441 being conducted?
This trial has 2 study locations across Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clonal Cytopenia of Undetermined Significance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
-
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.